TrialJournal of diabetes investigation2022

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.

Kenichi Shikata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.